Michael Handley

Michael Kevin Handley was the founder of Vessix Vascular, Inc., founded in 2011, where the title held was Vice President-Regulatory, Clinical & Quality from 2011 to 2012.
Current jobs include Chief Executive Officer at Aletheia Therapeutics, Inc.; Chairman, President & Chief Executive Officer at Sparta Healthcare Acquisition Corp.
since 2021; Chief Executive Officer & Director at Valion Bio, Inc. starting 2026; and Director at Makamer Holdings, Inc., Reven Holdings, Inc., Aletheia Therapeutics Corp., and Makamer, Inc. Former jobs include President, Chief Executive Officer & Director at Cleveland BioLabs, Inc.; CEO, VP-Regulatory, Business Development & Quality at AccelaPure Corp.
from 2005 to 2007; Chief Executive Officer & Director at Marizyme, Inc. from 2018 to 2019; President, Chief Executive Officer & Director at Biostax Corp.
in 2020; President, Chief Executive Officer & Director at Cytocom, Inc.; Chief Executive Officer & Director at Armis Biopharma, Inc. from 2012 to 2018; President, Chief Executive Officer & Director at Statera Biopharma, Inc. from 2021 to 2025; Chairman at Medavate Corp.; Director at Coeptis Therapeutics, Inc. from 2021 to 2022; Chief Compliance Officer & VP-Regulatory at Spectranetics LLC from 2007 to 2010; Global Head-Regulatory at Acclarent, Inc. from 2010 to 2011; and Senior Principal at PRTM Management Consultants LLC.
Education includes an undergraduate degree from Colorado State University in 1995 and an MBA from Pepperdine Graziadio Business School in 2001.